Plain-English translation of NCT05798897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing , a new type of cancer treatment that uses your own immune cells trained to recognize and fight lymphoma. Researchers will give you the treatment and watch carefully to see how safe it is and whether it helps control your cancer. The study is enrolling about 79 people with lymphoma that has returned or didn't respond to previous treatments.
Many people with lymphoma run out of standard treatment options, especially if their cancer comes back or doesn't respond to existing therapies. This medication represents a new approach using your body's own immune system, which may help people who have limited choices left.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive as an inpatient treatment. The study has two parts: first, doctors will carefully test different dose levels to find the safest amount, then they will give that dose to more patients to see how well it works. You will have regular blood tests and scans to monitor your health and whether your lymphoma is responding to the treatment.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States